Atlas Trials

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Clinical trial NCT04971226 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04971226
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Start date
2021-10-06
Primary completion
2023-11-28
Enrollment
405

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.